The efficacy of a multimodal analgesia protocol in preventing heterotopic ossification after acetabular fractures surgery

Adult Male Pain, Postoperative Cyclooxygenase 2 Inhibitors Ossification, Heterotopic Acetabulum Isoxazoles Middle Aged Combined Modality Therapy 3. Good health Fractures, Bone Young Adult 03 medical and health sciences Treatment Outcome 0302 clinical medicine Celecoxib Humans Pain Management Drug Therapy, Combination Female Analgesia Aged Retrospective Studies
DOI: 10.1007/s11096-017-0476-9 Publication Date: 2017-05-12T06:45:03Z
ABSTRACT
Background Heterotopic ossification (HO) after joint surgery is always a disturbing problem for patients and surgeons. Prophylaxis is the most effective therapy. Objective To assess the efficacy and safety of a multimodal analgesia protocol that included parecoxib and celecoxib in preventing HO after acetabular fracture surgery. Setting Selecting patients from trauma registry of our hospital. Method We identified 259 patients who had acetabular fracture surgery between January 2008 and December 2014. Hundredsixty-three patients received parecoxib and celecoxib (Group A) and 96 patients received no prophylaxis (Group B). The presence of HO was assessed according to the classification of Brooker et al. at the 12 month postoperative visit. Main outcome measure The differences in HO incidence and severity between the two groups. Results 49 patients (30.0%) developed HO in the Group A and 44(45.8%) in Group B. The difference in total HO incidence between the two groups was significant (P = 0.011 < 0.05, χ2 = 6.530, OR 0.508, 95% CI (0.301-0.857). Severe HO (Brooker grade III or IV) developed in 15 patients (9.2%) in Group A and 17 patients (17.7%) in Group B. Brooker grade I + II was 34(20.9%) and 27(28.1%) in each group. The difference in the severity of HO between the two Groups was significant (P = 0.008 < 0.05). Conclusion A short-term administration of parecoxib and celecoxib aids in the prevention of HO after acetabular fractures surgery.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (24)
CITATIONS (6)